Amylyx Pharmaceuticals launches $350M common stock offering

What happened

Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX), a pre-commercial pharmaceutical company developing therapies for endocrine conditions and neurodegenerative diseases, filed a preliminary prospectus supplement on August 18, 2026, for an offering of up to $350 million in shares of its common stock.

The company's stock closed at $35.11 on August 18, up 63.84% from the prior close of $21.43, on volume of about 23.9 million shares — more than 14 times its average volume. The filing notes the offering is subject to completion, and the underwriters may purchase up to an additional number of shares within 30 days.

The underwriters listed are Leerink Partners, Morgan Stanley, Guggenheim Securities, and LifeSci Capital.

Why the offering matters

Amylyx describes itself as a pre-commercial company with a pipeline including avexitide for post-bariatric hypoglycemia (PBH) and congenital hyperinsulinism, AMX0035 for Wolfram syndrome, AMX0114 for ALS, and AMX0318 for PBH and other rare diseases.

The company recently announced topline data from the Phase 3 LUCIDITY trial of avexitide in PBH, and the stock jumped sharply on the day of the filing. The prospectus does not state how the proceeds will be used; it refers to a 'Use of Proceeds' section in the full document.

The offering is a shelf takedown, meaning Amylyx is selling shares under a previously filed shelf registration statement on Form S-3 that became effective in March 2026.

What this means

A Form 424B5 is a prospectus supplement used to finalize the terms of a securities offering under an existing shelf registration. In this case, Amylyx is using its Form S-3 shelf to offer common stock. The company is a 'well-known seasoned issuer' under SEC rules, which allows the shelf to become automatically effective upon filing.

Common stock represents ownership in the company; each share gives the holder a claim on a portion of assets and earnings. The offering size of $350 million is the maximum gross proceeds, but the number of shares and price per share are not yet set — those blanks are filled in when the offering is priced.

The stock's sharp rise before the offering suggests investor enthusiasm, possibly tied to the LUCIDITY data. However, the filing does not explain the price move, and the company has not stated a specific reason for the offering beyond the general use of proceeds.

Typically, the next step is for the company to price the offering and issue shares, with delivery expected on or about a date in August 2026, as noted in the filing.